title: Cross talk of shear-induced production of prostacyclin and nitric oxide in endothelial cells.
abstract: We tested the hypothesis that vessel homeostasis is maintained through the cross talk of shear-induced production of prostacyclin and nitric oxide (NO). Confluent human umbilical vein endothelial cells (HUVEC) were exposed to fluid shear stress at 15 dyn/cm(2) using a cone-plate device, and the concentrations of 6-keto-PGF(1alpha) and NO metabolites (nitrate and nitrite) in the medium were measured with radioimmunoassay and the Greiss method, respectively. Compared with static control, shear stress increased cumulative prostacyclin production by twofold after 90 min of exposure. Inhibition of NO synthase enhanced flow-induced prostacyclin production by twofold without affecting the baseline production. Guanylyl cyclase inhibitor enhanced flow-induced prostacyclin production to the same degree. In contrast, a stable agonist of cGMP attenuated the rapid early phase of flow-dependent prostacyclin production. Shear-induced NO metabolite production was unaffected even after indomethacin inhibited prostacyclin production. We conclude that NO shows an inhibitory effect on prostacyclin production under shear stress and that vessel homeostasis may be maintained through an increase in prostacyclin production when NO synthesis is impaired in endothelial cells.
authors.affiliation: Second Department of Internal Medicine, Hirosaki University School of Medicine, Hirosaki 036-8562, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Osanai
authors.forename: N
authors.initials: N
authors.lastname: Fujita
authors.forename: N
authors.initials: N
authors.lastname: Fujiwara
authors.forename: T
authors.initials: T
authors.lastname: Nakano
authors.forename: K
authors.initials: K
authors.lastname: Takahashi
authors.forename: W
authors.initials: W
authors.lastname: Guan
authors.forename: K
authors.initials: K
authors.lastname: Okumura
mesh_terms: D002470:Cell Survival; D002478:Cells, Cultured; D006152:Cyclic GMP / Q000819:agonists / Q000031:analogs & derivatives / Q000494:pharmacology; D016861:Cyclooxygenase Inhibitors / Q000494:pharmacology; D004730:Endothelium, Vascular / Q000166:cytology / Q000378:metabolism* / Q000502:physiology; D004791:Enzyme Inhibitors / Q000494:pharmacology; D011464:Epoprostenol / Q000096:biosynthesis*; D016244:Guanosine 5'-O-(3-Thiotriphosphate) / Q000494:pharmacology; D006162:Guanylate Cyclase / Q000037:antagonists & inhibitors; D006801:Humans; D007213:Indomethacin / Q000494:pharmacology; D019331:NG-Nitroarginine Methyl Ester / Q000494:pharmacology; D009569:Nitric Oxide / Q000096:biosynthesis*; D019001:Nitric Oxide Synthase / Q000502:physiology; D052250:Nitric Oxide Synthase Type III; D013314:Stress, Mechanical
chemical_list: D016861:Cyclooxygenase Inhibitors; D004791:Enzyme Inhibitors; C016276:8-bromocyclic GMP; D009569:Nitric Oxide; D016244:Guanosine 5'-O-(3-Thiotriphosphate); D011464:Epoprostenol; C496314:NOS3 protein, human; D019001:Nitric Oxide Synthase; D052250:Nitric Oxide Synthase Type III; D006162:Guanylate Cyclase; D006152:Cyclic GMP; D019331:NG-Nitroarginine Methyl Ester; D007213:Indomethacin